文献速递主动脉疾病

血管腔内时代1000例腹主动脉瘤修复结局分析

Outcomes of the Repair of 1000 Abdominal Aortic Aneurysms in the Endovascular Era.
PubMed 文献 · Ann Vasc Surg · 2019-02-22

该回顾性队列研究分析了1998年至2014年间1000例腹主动脉瘤修复患者,其中开放手术占68.1%,腔内修复占31.9%。结果显示两种方式中期生存良好,EVAR可降低73.5岁以上患者早期死亡率,但73.5岁以下低中危患者EVAR无优势。

要点

  • EVAR组早期死亡率低于开放手术组(0.3% vs 1.9%,P=0.046)。
  • 73.5岁以下患者开放手术与EVAR死亡率无差异(P=0.996)。
  • 开放手术组再干预率更低(HR 1.93,95%CI 1.27-2.93,P=0.002)。

核心结论

  • 择期腹主动脉瘤修复无论开放手术或EVAR均提供良好的中期结局。
  • EVAR降低73.5岁以上患者早期死亡率;73.5岁以下低中危患者EVAR无优势,不应作为首选。

研究设计与样本

  • 回顾性队列研究,纳入1998年1月至2014年11月间1000例腹主动脉瘤修复患者,开放手术占68.1%,EVAR占31.9%。

主要发现

  • EVAR组吸烟者33.2% vs 21%(P<0.001),高胆固醇血症56.4% vs 41.1%(P<0.001),1型糖尿病11.3% vs 2.8%(P<0.001),缺血性心脏病36.4% vs 25.0%(P=0.013),慢性肾功能衰竭25.4% vs 16.2%(P<0.001),年龄74.6±7.1 vs 68.3±7.2岁(P<0.001)。
  • 开放手术组下肢慢性缺血22.8% vs 9.4%(P<0.001),动脉瘤直径61.2±13.6 vs 58.5±13.8 mm(P<0.001),瘤颈直径24.1±3.9 vs 23.3±3.0 mm(P=0.002),瘤颈长度15.1±11.1 vs 24.0±11.1 mm(P<0.001)。
  • 早期死亡率开放手术1.9% vs EVAR 0.3%(P=0.046);开放手术和年龄是早期死亡独立预测因素(OR 16.98,95%CI 1.97-146.29,P<0.001;OR 1.22,95%CI 1.09-1.36,P<0.001)。
  • 开放手术组术后并发症更多(23.9% vs 9.7%,P<0.001),早期再干预更多(4.4% vs 1.6%,P=0.026);EVAR组肾功能损害更常见(6.6% vs 3.5%,P=0.034),但多因素分析无统计学意义(OR 0.84,95%CI 0.41-1.69,P=0.618)。
  • 随访中位时间EVAR组33个月(范围0-175),开放手术组59个月(范围0-190);24和48个月生存率EVAR 92.9%和83.9%,开放手术94.6%和90.6%(P<0.001),多因素分析无统计学意义(HR 1.46,95%CI 0.99-2.12,P=0.060)。

关键数值与推荐

  • 年龄(HR 1.09,95%CI 1.06-1.11,P<0.001)、慢性阻塞性肺疾病(HR 1.39,95%CI 1.04-1.86,P=0.026)和慢性肾功能衰竭(HR 2.08,95%CI 1.51-2.87,P<0.001)与更差生存独立相关。

临床怎么用

  • 对于73.5岁以上患者,EVAR可降低早期死亡率,应优先考虑。
  • 73.5岁以下低中危患者,开放手术在再干预方面可能更优,EVAR不应作为首选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To analyze the outcome of abdominal aortic aneurysm (AAA) repair with elective open surgery (OS) versus endovascular aneurysm repair (EVAR) and assess the predictors of survival. METHODS: A retrospective cohort study was made of 1000 AAA treated between January 1998 and November 2014 (68.1% OS and 31.9% EVAR), with the comparison of comorbidity and complications, and survival analysis (Kaplan-Meier and Breslow). Multivariate logistic regression and Cox regression analyses were performed. RESULTS: The EVAR group had a higher prevalence of smokers (33.2% vs. 21%; P < 0.001), hypercholesterolemia (56.4% vs. 41.1%; P < 0.001), type 1 diabetes (11.3% vs. 2.8%; P < 0.001), ischemic heart disease (36.4% vs. 25.0%; P = 0.013), chronic renal failure (25.4% vs. 16.2%; P < 0.001), and an older age [74.6 ± 7.1 vs. 68.3 ± 7.2 (years); P < 0.001]. The OS group showed a greater prevalence of chronic ischemia of the lower extremities (22.8% vs. 9.4%; P < 0.001), a greater AAA diameter [61.2 ± 13.6 vs. 58.5 ± 13.8 (mm); P < 0.001], a greater aneurysm neck diameter [24.1 ± 3.9 vs. 23.3 ± 3.0 (mm); P = 0.002], and a shorter aneurysm neck length [15.1 ± 11.1 vs. 24.0 ± 11.1 (mm); P < 0.001]. Early mortality was low in both groups but higher with OS (1.9% vs. 0.3%; P = 0.046). OS [OR 16.98 (95% CI: 1.97-146.29) (P < 0.001)] and age [OR 1.22 (95% CI: 1.09-1.36) (P < 0.001)] were independent predictors of higher early mortality. However, there was no increase in mortality in the OS group in patients under 73.5 years (P = 0.996), and the differences increased over 73.5 years of age (P = 0.005). There were also more postoperative complications (23.9% vs. 9.7%; P < 0.001) and early reinterventions in the OS group (4.4% vs. 1.6%; P = 0.026). Only the prevalence of renal function impairment was greater in the EVAR group (6.6% vs. 3.5%; P = 0.034), but this complication resulted not significative in the multivariate analysis [OR 0.84 (95% CI: 0.41-1.69) (P = 0.618)]. The median duration of follow-up was 33 (range 0-175) and 59 months (range 0-190) for the EVAR and OS groups, respectively. The survival rate after 24 and 48 months was 92.9% and 83.9% (EVAR) versus 94.6% and 90.6% (OS) (P < 0.001). This difference was not significative in the multivariable analysis: hazard ratio (HR) 1.46 (95% CI 0.99 to 2.12); P = 0.060. OS also resulted in better freedom from reintervention rates for the same periods: 92.1% and 90.4% versus 92.9% and 88.1%, including multivariate analysis [HR 1.93 (95% CI 1.27 to 2.93) P = 0.002]. The factors independently associated to poorer survival were age [HR 1.09 (1.06-1.11); P < 0.001], chronic obstructive pulmonary disease [HR 1.39 (1.04-1.86); P = 0.026], and chronic renal failure [HR 2.08 (1.51-2.87); P < 0.001]. CONCLUSIONS: Elective AAA repair offers excellent middle-term outcomes with both OS and EVAR. EVAR reduces early mortality in the subgroup of patients older than 73.5 years. In patients younger than 73.5 years with a low to moderate surgical risk, EVAR offers no advantage over OS and therefore should not be regarded as the treatment of choice.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Revuelta Suero S, Martínez López I, Hernández Mateo M, et al. Outcomes of the Repair of 1000 Abdominal Aortic Aneurysms in the Endovascular Era. Ann Vasc Surg. 2019. PMID: 30802567. doi:10.1016/j.avsg.2018.12.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。